
VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.

Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.

VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.